Stocks · News reference
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of
Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics for cardiovascular, renal, and metabolic diseases using Atavistik's proprietary AMPS platform. Atavistik will receive $70 million upfront with potential milestone payments up to $1.9 billion plus tiered royalties, while Roche will handle preclinical and clinical development, regulatory, and commercialization activities.
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis Pharmaceuticals announced positive phase III results for two partnered programs: ulefnersen (FUSION study) for FUS-ALS met its primary endpoint with Otsuka planning regulatory discussions, and sefaxersen (IMAgINATION study) for IgAN showed statistically significant proteinuria reductions with Roche continuing the trial. These wins come after recent clinical setbacks in cardiovascular programs but follow FDA approval of Zanvastro for Alexander disease.